Impact of Pre-treatment With 600mg of Clopidogrel (Plavix) on the Incidence of Ischemic and Hemorrhagic Complications in Patients Undergoing Elective Percutaneous Coronary Revascularization.--Prospective Randomized Trial.
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Clopidogrel (Primary)
- Indications Embolism and thrombosis; Myocardial ischaemia
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 12 Apr 2017 Status changed from not yet recruiting to discontinued.
- 10 Mar 2008 Added lead investigator, from NCT.